Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Feb 2008

Weischer Maren, Bojesen Stig Egil, Ellervik Christina, Tybjaerg-Hansen Anne, Nordestgaard Børge Grønne

Abstract excerpt

PURPOSE: CHEK2*1100delC heterozygosity may be associated with an increased risk of breast cancer; however, it is unclear whether the evidence is sufficient to recommend genotyping in clinical practice. PATIENTS AND METHODS: We identified studies on CHEK2*1100delC heterozygosity and the risk of unselected, early-onset, and familial breast cancer through comprehensive, computer-based searches of PubMed, EMBASE, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis Regulatory Proteins
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Breast Neoplasms

Share to Checkpoint Kinase 2

Share to Genetic Carrier Screening

Share to Protein Serine-Threonine Kinases

Share to Risk Assessment

Source

Identifiers

PMID: 18172190
DOI: 10.1200/JCO.2007.12.5922

Genes

CHEK2
BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.PMID 18172190Read ↗

Increased risk of breast cancer associated with CHEK2*1100delC.Semantic proximity Read ↗

CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls.Semantic proximity Read ↗

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.Semantic proximity Read ↗

CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.Semantic proximity Read ↗

A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients.Semantic proximity Read ↗

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.Semantic proximity Read ↗

Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.Semantic proximity Read ↗

CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.Semantic proximity Read ↗

The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.Semantic proximity Read ↗

The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry.Semantic proximity Read ↗

Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the <i>CHEK2*1100delC</i> Germline MutationSemantic proximity Read ↗

CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.